Detalhe da pesquisa
1.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
N Engl J Med
; 373(18): 1697-708, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26510020
2.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28600210
3.
Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE): study protocol for a partially randomised patient preference study.
BMJ Open
; 13(9): e073817, 2023 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37734892
4.
What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK.
Trials
; 19(1): 15, 2018 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29310685
5.
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials.
Trials
; 23(1): 1004, 2022 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36510242
6.
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Cancer Discov
; 7(9): 1006-1017, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28450425
7.
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Nat Commun
; 7: 13294, 2016 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27827358